Imovax D.T. Adult (Diphtheria Toxoid, Tetanus Toxoid, Algeldrate)

The vaccine contains chemically inactivated diphtheria and tetanus toxins (toxoids). When injected, the toxoids are processed by antigen‑presenting cells, which activate T‑helper cells and stimulate B‑cells to produce specific IgG antibodies. These antibodies neutralize the natural toxins, and memory cells provide long‑term protection.

The dosing schedule is determined by the prescribing healthcare professional. Typically, a single intramuscular dose is given, followed by booster doses at intervals recommended by national immunization guidelines or the treating physician.

Safety data for use in pregnancy and lactation are limited. The vaccine should only be administered when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Imovax D.T. Adult product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Imovax D.T. Adult contains diphtheria and tetanus toxoids similar to other licensed vaccines, but it may differ in preservative composition (e.g., algeldrate) and specific manufacturing processes. Clinical efficacy and safety profiles are comparable, while formulation differences can affect storage requirements and handling.

The vaccine must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must never be frozen or shaken. Proper cold‑chain management is essential to maintain potency until administration.

Imovax D.T. Adult is given by a single intramuscular injection, usually into the deltoid muscle, or subcutaneously if intramuscular administration is not feasible. The injection should be performed by a qualified healthcare professional using aseptic technique.

The most serious adverse events include severe allergic reactions such as anaphylaxis and, rarely, neurologic conditions like Guillain‑Barré syndrome. Immediate medical attention is required if symptoms such as difficulty breathing, swelling of the face or throat, or rapid onset of weakness occur after vaccination.

Individuals with a known hypersensitivity to any component of the vaccine, including diphtheria or tetanus toxoids or the preservative algeldrate, should not receive it. Persons with severe immunodeficiency or those who have experienced a serious reaction to a previous dose should also avoid this vaccine.